

ANUH PHARMA LTD.

Reqd. Office : ,3-A, North Wing, Shiv Sagar Estate, Dr. Annie Basent Road, Worli, Mumbai-400018

AUDITED FINANCIAL RESULT FOR THE QUARTER ENDED 31st March -2012

Sr. No.	Particulars	Unaudited			Audited	
		Quarter ended			Current year ended 31/03/2012	Previous year ended 31/03/2011
		Current Year 31.03.2012	Current Year- 31.12.2011	Previous Year 31.03.2011		
						Rs. In Lacs
1	(a) Revenue From Operation	4839.69	6644.25	4009.60	22609.43	17,643.07
2	Expenditure					
a	(Increase)/Decrease in Inventories	(74.24)	(69.19)	10.57	(309.40)	(31.86)
b	Cost of Materials Consumed	4121.42	4767.77	2981.43	18210.04	13,496.35
c	Purchases of Stock -in-Trade	130.85	666.74	327.89	1011.25	1,294.57
d	Employee Benefit Expense	71.33	85.71	79.16	320.09	280.46
e	Processing Charges	71.58	45.29	55.18	240.85	174.13
f	Power Fuel & Other Utility	57.40	64.60	49.70	255.73	164.92
g	Depreciation	41.02	31.13	32.19	132.15	110.67
h	Other Expenses	220.05	215.48	177.24	778.82	646.94
	Total :-	4639.41	5807.53	3713.36	20639.53	16,136.18
3	Profit From Operation before Interest & Exceptional Item (1-2)	200.28	836.72	296.24	1969.90	1,506.89
4	a Other Income	116.89	37.91	103.60	298.52	260.96
	b Exchange Gain/(Loss)	102.65	(368.80)	(13.31)	(413.56)	5.16
5	Profit before Finance Cost & Exceptional Items(3+4)	419.82	505.83	386.53	1854.86	1773.01
6	Finance Cost	32.49	1.31	3.42	49.86	22.24
7	Profit after Finance Cost but before Exceptional Item(5-6)	387.33	504.52	383.11	1805.00	1750.77
8	Exceptional Item	0.00	0.00	0.00	0.00	0.00
9	Profit(+) / Loss(-) before Tax (7+8)	387.33	504.52	383.11	1805.00	1750.77
10	Tax Expenses	95.39	155.00	107.00	520.39	521.81
11	Net Profit(+) / Loss(-) from Ordinary Activities after Tax (9-10)	291.94	349.52	276.11	1284.61	1228.96
12	Extraordinary Item (Net of Tax Expenses)	0.00	0.00	0.00	0.00	0.00
13	Net Profit(+) / Loss(-) for the period (11-12)	291.94	349.52	276.11	1284.61	1228.96
14	Paid up Equity Share Capital	417.60	417.60	417.60	417.60	417.60
15	Reserves excluding Revolution Reserves as per Balance sheet of Previous Accounting Year				6,503.00	5,176.00
16	Earning per Share(EPS) Face Value of Rs.5/-					
a	Basic & Diluted EPS before Extraordinary items for the period, for the year to date and for the previous year(not to be annualised)	3.50	4.18	3.31	15.38	14.71
b	Basic & Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year(not to be annualised)	3.50	4.18	3.31	15.38	14.71
			12.00			
			13.00			
17	Public Shareholding		14.00			
	Number of Shares	2922662	15	29,12,412	2922662	29,12,412
	Percentage of Shareholding	34.98	16.00	34.87	34.98	34.87
18	Promoters & Promoter group Shareholding		17.00			
a	Pledged/Encumbered					
	-Number of Shares	Nil	Nil	Nil	Nil	Nil
	-Percentage of Shares(as a % of the total share holding of promoters and promoter group)					
3	Figures of the last quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figures upto the third quarter of the current financial year.					
4	The Company's operation fall under single segment namely "Bulk Drugs & Chemicals".					
5	The Board of Directors have recommended a dividend of Rs. 5.50 per share for the year ended 31.03.2012 subject to the approval of the shareholders.					
6	Number of Investors complaints (i) received during the quarter :1 (ii) disposed off : 1 (iii) pending at the quarter end : Nil.					
Place :	Mumbai					
Date :	30th May, 2012					

ANUH PHARMA LIMITED
STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH 2012

(Amount in `)

Particulars	Note No.	As at 31March, 2012	As at 31March, 2011
1	2	3	4
I. EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share capital	1	4,17,60,000	4,17,60,000
(b) Reserves and surplus	2	65,02,97,881	57,15,99,116
(c) Money received against share warrants		-	-
Sub Total		69,20,57,881	61,33,59,116
2 Share application money pending allotment		-	-
3 Non-current liabilities			
(a) Long-term borrowings		-	-
(b) Deferred tax liabilities (Net)		-	-
(c) Other Long term liabilities		-	-
(d) Long-term provisions	3	11,52,899	14,46,965
Sub Total		11,52,899	14,46,965
4 Current liabilities			
(a) Short-term borrowings	4	1,30,24,164	7,02,26,231
(b) Trade payables	5	29,43,51,842	22,49,43,900
(c) Other current liabilities	6	2,68,73,768	10,34,52,710
(d) Short-term provisions	7	16,28,79,816	22,63,05,448
Sub Total		49,71,29,590	62,49,28,289
TOTAL EQUITY AND LIABILITIES		1,19,03,40,370	1,23,97,34,370
II. ASSETS			
Non-current assets			
1 (a) Fixed assets	8		
(i) Tangible assets		7,48,94,072	8,10,45,769
(ii) Intangible assets		3,04,184	2,02,886
(iii) Capital work-in-progress		3,42,79,922	2,15,28,231
(iv) Intangible assets under development		-	-
Sub Total		10,94,78,178	10,27,76,886
(b) Non-current investments	9	25,06,18,000	13,62,00,000
(c) Deferred tax assets (net)	10	11,69,988	1,73,110
(d) Long-term loans and advances	11	66,85,509	59,65,534
(e) Other non-current assets		-	-
Sub Total		25,84,73,497	14,23,38,644
2 Current assets			
(a) Current investments	12	7,51,25,006	17,68,24,281
(b) Inventories	13	12,59,21,211	16,90,01,265
(c) Trade receivables	14	39,08,84,569	25,35,95,436
(d) Cash and bank balances	15	6,64,30,078	8,77,55,860
(e) Short-term loans and advances	16	16,32,36,264	30,64,60,657
(f) Other current assets	17	7,91,568	9,81,340
Sub Total		82,23,88,695	99,46,18,840
TOTAL ASSETS		1,19,03,40,370	1,23,97,34,370